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Background: Meningioma was the first solid tumor shown to contain a recurrent genetic alteration e.g. monosomy
22/del(22q), NF2 being the most relevant gene involved. Although monosomy 22/del(22q) is present in half of all
meningiomas, and meningiomas frequently carry NF2 mutations, no study has been reported so far in which both
alterations are simultaneously assessed and correlated with the features of the disease.
Methods: Here, we analyzed the frequency of both copy number changes involving chromosome 22 and NF2
mutations in 20 sporadic meningiomas using high-density SNP-arrays, interphase-FISH and PCR techniques.
Results: Our results show a significant frequency of NF2 mutations (6/20 patients, 30%), most of which (5/6) had
not been previously reported in sporadic meningiomas. NF2 mutations involved five different exons and led to a
truncated protein (p.Leu163CysfsX46, p.Phe62LeufsX61, p.Asp281MetfsX15, p.Phe285LeufsX11, p.Gln389ArgfsX37)
and an in frame deletion of Phe119. Interestingly, all NF2 mutated cases were menopausal women with monosomy
22 but not del(22q).
Conclusions: These results confirm and extend on previous observations about the high frequency and
heterogeneity of NF2 mutations in sporadic meningiomas and indicate they could be restricted to a well-defined
cytogenetic and clinical subgroup of menopausal women. Further studies in large series of patients are required to
confirm our observations.
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Meningioma was the first type of solid tumor which
already in 1967, was shown to contain a specific recurrent
genetic alteration consisting of loss of a chromosome 22 in
around half of the cases [1]. The association observed
between the dominantly-inherited neurofibromatosis type-2
syndrome and central nervous system (CNS) tumors such
as meningiomas and schwannomas, has rapidly led to
the identification of the NF2 gene located in chromosome
22q as a candidate predisposing gene in both familial and
sporadic meningiomas [2,3]. However, loss of chromosome* Correspondence: taberner@usal.es
1Instituto de Estudios Ciencias de la Salud de Castilla y León (IECSCYL),
Soria, Spain
2Instituto de Investigación Biomédica de Salamanca (IBSAL),
Salamanca, Spain
Full list of author information is available at the end of the article
© 2013 Tabernero et al.; licensee BioMed Cen
Commons Attribution License (http://creativec
reproduction in any medium, provided the or22 and/or del(22q) are only found in a fraction of all
meningiomas suggesting that molecular and chromosomal
changes other than those targeting the NF2 gene may also
be involved in the development of meningiomas [4,5].
Since the earliest reports till 1994, more than 400 different
NF2 mutations have been described in meningiomas
[6-27]; however, the precise significance of the NF2 gene
status in sporadic meningiomas remains unclear. Based
on sequencing data from the literature, NF2 mutations may
involve all exons of the gene except exon 16. Interestingly,
an association between NF2 gene mutations and specific
subtypes of meningiomas such as fibroblastic and transi-
tional tumors has been observed [7-9,24], although such
data could not be always confirmed in other series [28].
In this study, we report on the frequency of NF2 muta-
tions in a group of 20 sporadic WHO grade I/benigntral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and histopathological subtypes of meningiomas. At the
same time, we also review the literature reported so far on
NF2 mutations in meningiomas. Overall, six distinct NF2
mutations were found (6/20 cases; 30%) five of which had
not been previously reported in sporadic meningiomas
[10,24,29]. Noteworthy, NF2-mutated tumors were sys-
tematically associated with complete loss of chromosome
22 (monosomy 22) but not del(22q), usually in the absence
of additional genetic alterations involving other chromo-
somes as assessed by both interphase fluorescence in situ
hybridization (iFISH) and single nucleotide polymorphism
(SNP) arrays. These results, together with the higher
median age and the slightly greater frequency of transitional
meningiomas, among the mutated cases, suggest that
NF2-mutated tumors may represent a uniquely well-defined
subgroup of sporadic meningiomas.Methods
Patients and samples
A total of 20 adult WHO grade I (sporadic) meningioma
patients (3 males and 17 females; mean age of 60 ± 16 years)
were included in this study. Prior to entering the study,
informed consent was given by each individual and the
study was approved by the ethics committee of the
University Hospital of Salamanca (Salamanca, Spain).
Classification of meningioma was established according to
the WHO criteria, with the following distribution: menin-
gothelial meningiomas, 10 cases; transitional, 7, and; fibro-
blastic meningiomas, 3 tumors. In each individual patient,
paired fresh EDTA-anticoagulated peripheral blood (PB)
and tumoral samples were obtained in parallel and stored
in liquid nitrogen (−150°C), until analysed.DNA extraction
Both tumoral and PB cells’ DNA was extracted using
the QIAamp DNA mini kit (Qiagen, Hilden, Germany)
following the instructions of the manufacturer. A Nano-
Drop-1000 Spectrophotometer (Nano-Drop Technologies,
Wilmington, DE, USA) was used to quantify the amount
of DNA obtained and assess its quality.Copy number alterations and loss of heterozygosity (LOH)
of chromosome 22 by iFISH and SNP-arrays
In order to confirm the presence of numerical changes
involving chromosome 22, iFISH studies were performed
with commercially available probes for chromosome 9
and 22q (LSI bcr/abl ES DC Probe). In addition, in 15/20
patients copy number alterations and LOH were analyzed
with the GeneChip Human Mapping 250 K Nsp and 250 K
Sty-arrays (Affymetrix), as previously reported [30].Identification of NF2 mutations
DNA from the 20 meningioma samples was amplified by
conventional PCR [20]. In order to identify mutations in
the NF2 gene sequence, 32 customized primers were used.
Oligonucleotide primer sequences were obtained from the
UniSTS database at NCBI (www.ncbi.nlm.nih.gov).
PCR products were analysed by capillary electrophoresis
using an ABI 3130xl instrument (Applied Biosystems,
Foster City, CA, USA) and the Chromas (Technelysium
Pty Ltd, http://technelysium.com.au) software was used to
analyze the DNA sequences obtained.
Statistical analyses
The statistical significance of differences observed between
groups was assessed by the Student T and the Mann–
Whitney U tests, for parametric and non-parametric
(continuous) variables, respectively; for qualitative variables,
the X2 test was used (SPSS software, SPSS 15.0, SPSS Inc,
Chicago, IL, USA). P-values <0.05 were considered to be
associated with statistical significance.
Results
Frequency, localization and type of NF2 mutations in
sporadic meningiomas
NF2 gene mutations were found in 6/20 meningiomas
studied (30%) (Table 1). Specific NF2 mutations identified
consisted of four deletions of a single base, one deletion of
3 bp and a duplication of 19 bp, (Figure 1). Therefore,
changes in cDNA consisting of a c.186delT, c.841delG,
c.855delT and c.1165delC were found in those four cases
with single nucleotide deletions, such mutations generating
the synthesis of the p.Phe62LeufsX61, p.Gln389ArgfsX37,
p.Asp281MetfsX15 and p.Phe285LeufsX11 truncated pro-
teins, respectively (Figure 1). The remaining deletion iden-
tified involved three consecutive bp (“CTT”) at exon 3
(c.357_359del) also leading to an in frame deletion of
Phe119, and the duplication of 19 bp involved positions
469 to 487 of the NF2 gene, leading to a p.Leu163Cys
mutated nf2 protein with a stop after 46 codons (Figure 1).
Association between NF2 mutations and other
chromosomal changes
From the 20 meningiomas analyzed, 7 showed a diploid
karyotype (35%), another 6 (30%) had an isolated loss of
chromosome 22, two or more chromosomal changes
including loss of chromosome 22q were found in another
5 cases –monosomy 22 in 3 (15%) and del(22q) in the
other 2 patients (10%)– and two meningiomas displayed
multiple chromosomal losses/gains in the absence of
monosomy 22/del(22q) (n = 2; 10%) (Table 1).
Interestingly, all 6 NF2-mutated tumors carried mono-
somy 22, which was the only chromosomal alteration
in 4/6 cases. Consequently, NF2-mutated meningiomas
accounted for most cases associated with monosomy 22
Table 1 Clinical, histopathological and genetic characteristics of meningioma patients grouped according to the
presence vs absence of NF2 gene mutations (n = 20)
Patient features NF2-mutated meningiomas Non-mutated meningiomas p-value
(n = 6) (n = 14)
Age (median in years) 73 (56–82) 53 (26–80) 0.03
Gender (Male/Female) 0/6 3/11 0.32
(0%/100%) (21%/79%)
Skull base 1 (17%) 7 (50%)
Tumor localization Convexity 1 (17%) 2 (14%) 0.37
Tentorium 4 (66%) 4 (29%)
Spinal 0 (0%) 1 (7%)
Histological subtype Meningothelial 2 (33%) 8 (57%)
Transitional 3 (50%) 4 (29%) NS
Fibroblastic 1 (17%) 2 (14%)
Chromosome 22 status by iFISH Diploid 0 (0%) 9 (64%) 0.005
del(22q) 0 (0%) 3 (22%)
Monosomy 22 6 (100%) 2 (14%)
Cytogenetic subgroups Diploid 0 (0%) 7 (50%) 0.03
Isolated monosomy 22 4 (67%) 2 (14%)
Complex-karyotype: with monosomy 22 2 (33%) 1 (7%)
with del(22q) 0 (0%) 2 (14%)
Complex-karyotype w/o −22/del(22q) 0 (0%) 2 (14%)
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67%) or with monosomy 22 combined with other chromo-
somal alterations (2/6, 33%); conversely, among all other
cases except three, which were either diploid for chromo-
some 22, carried del(22q) or had multiple chromosomal
losses/gains in the absence of monosomy 22/del(22q),
showed no NF2 mutations (0/11; p = 0.03)(Table 1).
Chromosome 22 copy number alterations and LOH by
SNP-arrays
As described above, iFISH showed losses of chromosome
22 in 11 cases; such losses consisted of monosomy 22 (9
cases; 45%) and del(22q) (2 cases; 10%) extending from the
18.207.392 bp position to the telomere of chromosome 22q
(Figure 2 and Table 2). Noteworthy, LOH was investigated
by SNP-arrays in 15/20 meningiomas, and it was found to
involve chromosome 22 in 7/8 cases that had monosomy
22 and in 1/2 cases with del(22q). The number of chromo-
some 22 SNPs showing LOH varied between 3 and 920
SNPs. Among these patients, four SNPs (e.g., rs2857648,
rs2857652, rs2530678 and rs1009147) were found to be
associated with LOH for the NF2 gene (Figure 2).
Association between NF2 mutations and other features
of the disease
Interestingly, all NF2-mutated meningiomas corresponded
to female patients (6/6 vs 11/14, p > 0.05) with a highermedian age vs all other cases (73 vs 53 years; p = 0.03)
(Table 1). By contrast, a similar localization pattern was
observed for the 6 NF2-mutated tumors and the other 14
non-mutated meningiomas (Table 1).
From the histopathological point of view, the 6 NF2
mutated benign/grade I meningiomas showed a variable
histology including 3 transitional meningiomas, two menin-
gothelial tumors and one fibroblastic tumor, the frequency
of transitional tumors being slightly higher than among
non-mutated cases (3/6 vs 4/14 cases; p > 0.05) (Table 1).
Discussion
Many studies have confirmed that loss of genetic material
from chromosome 22 is by far the most frequent chromo-
somal alteration in meningiomas, being detected in around
half of the cases. Such losses of chromosome 22 are
heterogeneous and while they most frequently involve the
whole chromosome (monosomy 22), in another substantial
proportion of cases it consists of del(22q) with variable
breakpoints, both alterations –monosomy 22 and del
(22q) − being found either as the only chromosomal alter-
ation or in combination with distinct alterations involving
other chromosomes [30,31]. In parallel, multiple studies
have also shown a variable frequency (between 14% and
78% of the cases) of NF2 gene mutations in heterogeneous
series of meningiomas consisting of between 12 to 170
patients [18,27], some of these reports specifically focusing
Figure 1 NF2 mutations. Detailed description of the 6 NF2 mutations (a 19 bp duplication and 5 deletions) identified among the 20
meningiomas analyzed, including the position of the alterations identified, the potential effect of each mutation and their sequencing
chromatograms (the positions of the deleted base(s) are indicated with an arrow).
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recurrent meningiomas [6], rare histopathological subtypes
[9] or patients affected by multiple meningiomas [12].
Recurrent chromosomal losses deviating from normal gene
dosage present in tumor cells of various types, frequently
point out the existence of one or more underlying tumor
suppressor genes coded in the deleted DNA sequences.
Because of this and the development of meningiomas in
patients with neurofibromatosis carrying mutations of the
NF2 gene coded at chromosome 22q12.2, NF2 has long
been considered as the most relevant gene targeted by
chromosome 22 losses in meningiomas [7,32]. However,
careful analysis of the studies reported so far reveals that
the association between chromosome 22 status and the
presence of NF2 mutations has not been investigated in
detail in sporadic meningiomas.
In the present study, we demonstrate the existence of a
close association between NF2 mutation and monosomy22 but not del(22q), in sporadic meningiomas. Whereas
most cases with monosomy 22 showed NF2 mutations,
these were absent in all three patients who showed del
(22q). Altogether, these findings suggest that the NF2 gene
would only be involved in the pathogenesis of a well-
defined subset of all meningiomas, typically in association
with monosomy 22. Of note, a few cases showed mono-
somy 22 in the absence of NF2 mutations; these results
support previous observations indicating that in meningi-
omas, monosomy 22 is typically found at higher frequen-
cies than NF2 mutations, although the frequency of both
alterations also depends on the detection method. This,
together with the observation that NF2 mutations were
always present in heterozygosis, could suggest that muta-
tions of the NF2 gene could be a secondary event in the
development of meningiomas which would occur after the
loss of chromosome 22 and that therefore, inactivation of
other genes coded in chromosome 22 (e.g. SMARCB1
Figure 2 LOH profiles of chromosome 22 and the NF2 gene in sporadic meningiomas (n = 15). Rows (n = 6206) correspond to individual
SNPs along the entire chromosome 22 and columns identify different meningiomas. Blue indicates presence of LOH, allele retention is shown in
yellow, while red indicates conflict between PB DNA and tumor DNA SNP calls (AA or BB in PB and AB or BB and AB or AA in the tumor sample,
respectively), and absence of call for non-informative SNPs (AA or BB) are depicted in white and grey, respectively. Two tumors (M7 and M12)
showed a pattern compatible with biclonal allele deletions with copy number value of 1 in the absence of LOH. The NF2 gene locus containing
16 SNPs in the array is amplified in the right side of the figure to better show the status of those SNPs heterozygously distributed in introns 1, 4,
6, 8, 10, 11, 14 and 15. LOH for three NF2-associated SNPs was found in one tumor (M6), for two SNPs in another case (M11) and for one SNP in
another two meningiomas (M16 and M18).
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ment, even among NF2 mutated cases. In line with this
hypothesis, NF2- mutated meningiomas also showed a
rather low incidence of LOH of the NF2 gene by SNP-
arrays. However, other mechanisms e.g. rearrangements
identifiable by MPLA and other techniques, together with
mutations in promoter and other non coding regions, andTable 2 Chromosome 22 status by iFISH vs SNP-arrays perfor
Tumor iFISH Karyotype Chromos
ID Chromosome 22 status Copy nu
M20 −22q −22 1.35 (
M18 −22q −22 1.19 (
M15 Complex & -22q −22 1.30 (
M14 −22q −22 1.34 (
M13 −22q −22 1.24
M11 Complex & -22q −22 1.20 (
M16 −22q −22 1.27 (
M7 −22q,-Y −22 1.52 (
M12 Complex & del(22q) del(22q11.22-qter) 1.50
M6 Complex & del(22q) del(22q11.22-qter) 1.34
M19 Complex Diploid 1.58 (
M10 Complex Diploid 1.71 (
M9 Diploid Diploid 1.75 (
M8 Diploid Diploid 1.92
M5 Diploid Diploid 1.79
*LOH and copy number analyses involved 6206 SNP localized along the entire chro
iFISH interphase fluorescence in situ hybridization, SNP single nucleotide polymorphepigenetic mechanisms leading to inactivation of NF2 gene
expression, may also be involved and should be investi-
gated to confirm or rule out this hypothesis. Of note,
among cases with monosomy 22/del(22q) in the absence of
NF2 mutations, two patients showed lack of LOH, which
could be related to the greater percentage of non-tumoral
diploid cells present in both patients (data not shown) [34].med in 15/20 sporadic meningiomas
ome 22 status by SNP arrays* (n = 6206)
mber values N. of SNPs with LOH/N. of informative SNPs (%)
1.01-1.93) 108 / 1326 (8%)
0.76-1.59) 365 / 1131 (32%)
0,85-2,03) 454 / 1158 (39%)
0.95-1.77) 80 / 1472 (5%)
(0.92-1.8) 920 / 1188 (77%)
0.91-1.91) 694 / 1043 (67%)
0.81-1.75) 209 / 1340 (16%)
1.08-2.14) 18 / 1505 (1%)
(0.98-2) 19 / 1683 (2%)
(0.8-2.55) 763 / 1195 (64%)
1.12-2.06) 7 / 1630 (0.4%)
1.09-2.31) 9 / 1770 (0.5%)
1.27-2.32) 3 / 1712 (0.2%)
(1.6-2.39) 5 / 1681 (0.3%)
(1.28-2.3) 3 / 1696 (0.2%)
mosome 22.
ism, LOH loss of heterozigosity.
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histopathological features of the meningiomas patients
studied at diagnosis, showed unique features for those
sporadic tumors carrying NF2-mutations in association
with monosomy 22. Accordingly, these cases systematic-
ally corresponded to older menopausal women, they more
frequently showed a meningothelial histopathological
appearance, and none of them had relapsed so far. These
results suggest that NF2-mutated sporadic meningiomas
may correspond to a unique cytogenetic and clinical sub-
type of meningiomas, which emerge at relatively advanced
ages. In line with this hypothesis, previous studies also
suggested the existence of a relationship between NF2 gene
mutations and the histology of meningiomas (e.g. transi-
tional tumors [24]); however, this association remains
controversial and in our series, the association between
NF2 mutated and transitional meningiomas did not reach
statistical significance, in line with the findings of several
groups [7,8,21].
Despite different mutations involving distinct exons of
the NF2 gene were found in each NF2-mutated meningi-
oma case, they led to a truncated protein or a small inTable 3 Frequency of NF2-gene mutations in our patients and
sporadic meningiomas
Reference No of mutated cases/
Ruttledge, et al., 1994 [27]** 24/170 (14
LeKanne Deprez, et al., 1994 [26]** 19/48 (40
Merel, et al., 1995 [25]** 15/57 (26
Wellenreuther, et al., 1995 [24] 41/70 (59
Ng, et al., 1995 [23] 7/26 (27%
Papi, et al., 1995 [22]** 9/61 (15%
Harada, et al., 1996 [21] 8/23 (35%
Ruttledge, et al., 1996 [20] 67/111 (60
De Vitis, et al., 1996 [29] 37/125 (30
Stangl, et al., 1997 [18] 10/12 (83
Leone, et al., 1999 [17]** 11/81 (14
Ueki, et al., 1999 [16] 10/50 (20
Evans, et al., 2001 [14] 4/27 (15%
Joachim, et al., 2001 [13]* 26/61 (43
Szijan, et al., 2003 [11] 5/14 (35%
Lomas, et al., 2005 [10]** 21/88 (24
Hartmann, et al., 2006 [9]# 21/80 (20
Kim, et al., 2006 [8]** 20/42 (48
Hansson, et al., 2007 [7]** 39/100 (39
Goutagny, et al., 2010 [6]& 14/18 (78
Tabernero et al. (2013) 6/20 (30%
Total 414/1284 (3
*several radiation-induced meningiomas were included in this series; #infrequent su
showing progression were analyzed in this series.
**not all exones of the NF2 gene were investigated in this series.frame deletion and therefore, potentially also to a loss of
(normal) function of the nf2 protein. Overall these findings
are in line with the great heterogeneity of NF2 mutations
reported so far in the literature (Table 3). In fact, previous
studies indicate that multiple distinct substitutions or
deletions of one or more nucleotides may occur and that
all NF2 gene exons, except exon 16, may be involved
(Table 3), exon 2 being the most frequently mutated
(≈45% of all mutated tumors). Among our cases, deletions
of one and three nucleotides together with duplication of
a sequence of 20 nucleotides, were observed. Of note, with
the exception of one mutation which had been previously
described, none of the other five NF2 gene mutations
identified in our cases had been reported before in sporadic
meningiomas (Table 3).
Conclusions
In the present study we confirm the relatively high fre-
quency of distinct NF2 mutations leading to a truncated
protein in sporadic meningiomas, most of the identified
genetic changes corresponding to mutations which had not
been previously described. Interestingly, a clear associationother series from the literature reporting >10
total cases (%) Exons involved
%) 2-7-8-9-10-11-12
%) 1-2-3-4-5-6-11-12
%) 1-2-3-4-5-6-7-8-9-12-13
%) 1-2-3-4-5-6-7-8-10-11-12-13
) 4-5-6-7-10
) 2-5-7-8-11
) 1-2-5-8-11-12
%) 1-2-3-4-6-7-8-10-11-12-13-14-15-17
%) 2-3-4-5-6-7-8-11-12-13
%) 3-5-6-7-8-11-12
%) 2-7-11
%) 4-5-7-10-12-13
) 3-4-8-13
%) 1-2-3-4-5-6-7-8-10-11-12-13
) 2-3-8-12-13
%) 1-2-3-4-7-11-12-13
%) 1-2-3-4-5-6-7-8-9-11-12-13-14-15
%) 1-2-4-5-7-10-11-12
%) 1-2-3-4-6-7-8-9-10-12-13-14
%) 2-5-6-7-8-10-11-12-13
) 2-3-5-9-12
2%) 1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-17
btypes of meningiomas were analyzed in this series; &meningioma cases
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http://www.biomedcentral.com/1471-2350/14/114was found among our cases between mutation of the NF2
gene and monosomy 22, but not del(22q); in addition, all
NF2-mutated cases corresponded to older menopausal
women, supporting the notion that NF2-mutated patients
could represent a well-defined and unique cytogenetic and
clinical subtype of meningiomas in which acquisition of
monosomy 22 could be sequentially followed by NF2
mutation during the development of the disease. Further
studies in large series of meningioma patients are required
to confirm these observations.
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